ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology1997
Biopharmaceutical aspects of lipid formulations of amphotericin B.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Plasma Bead Entrapped Liposomes as a Potential Drug Delivery System to Combat Fungal Infections.Molecules (Basel, Switzerland) · 2022Article
- Combination of Posaconazole and Amphotericin B in the Treatment ofMicroorganisms · 2018Article
- Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.Pathogens (Basel, Switzerland) · 2017Article
- Improved antifungal activity of amphotericin B-loaded TPGS-b-(PCL-ran-PGA) nanoparticles.International journal of clinical and experimental medicine · 2015Article
- Review
- Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.Antimicrobial agents and chemotherapy · 2006Article
- Optimizing efficacy of amphotericin B through nanomodification.International journal of nanomedicine · 2006Review
- Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.Antimicrobial agents and chemotherapy · 2004Article
- Newer antifungal agents.Indian journal of pediatrics · 2004Review
- Aspergillus fumigatus and aspergillosis.Clinical microbiology reviews · 1999Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To improve the clinical utility of amphotericin B (AmpB), several lipid-based formulations have been developed. The biopharmaceutical aspects related to the parenteral use of colloidal lipid particles as carriers of AmpB are reviewed here. The first part of the review provides an introduction to the parenteral use of colloidal particles for chemotherapy by addressing the concept of a particulate drug carrier system, the pharmaceutical technological issues, and the biological factors governing the potential and limitations of lipid particles for effective drug delivery. The second part is devoted to AmpB lipid formulations. The pharmaceutical characteristics of the various industrially produced formulations, their pharmacokinetics and possible mechanisms of action, and potential future developments are described.
Indexed as
Identifiers
9063676What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.